WO2004100947A3 - Novel chemical compounds - Google Patents
Novel chemical compounds Download PDFInfo
- Publication number
- WO2004100947A3 WO2004100947A3 PCT/US2004/013668 US2004013668W WO2004100947A3 WO 2004100947 A3 WO2004100947 A3 WO 2004100947A3 US 2004013668 W US2004013668 W US 2004013668W WO 2004100947 A3 WO2004100947 A3 WO 2004100947A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chemical compounds
- novel chemical
- treating
- proliferative diseases
- ans
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006532540A JP2006528685A (en) | 2003-05-06 | 2004-04-29 | New compounds |
US10/555,796 US7592352B2 (en) | 2003-05-06 | 2004-04-29 | Substituted thieno and furo-pyridines |
EP04760864A EP1620094A4 (en) | 2003-05-06 | 2004-04-29 | Novel chemical compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46817503P | 2003-05-06 | 2003-05-06 | |
US60/468,175 | 2003-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004100947A2 WO2004100947A2 (en) | 2004-11-25 |
WO2004100947A3 true WO2004100947A3 (en) | 2005-03-24 |
Family
ID=33452188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/013668 WO2004100947A2 (en) | 2003-05-06 | 2004-04-29 | Novel chemical compounds |
Country Status (4)
Country | Link |
---|---|
US (1) | US7592352B2 (en) |
EP (1) | EP1620094A4 (en) |
JP (1) | JP2006528685A (en) |
WO (1) | WO2004100947A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050026944A1 (en) * | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
US7202363B2 (en) * | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
EP1858877B1 (en) | 2005-01-14 | 2014-03-12 | Gilead Connecticut, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US7566721B2 (en) | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
JP2009504692A (en) * | 2005-08-16 | 2009-02-05 | エフ.ホフマン−ラ ロシュ アーゲー | Novel 4-amino-thieno [3,2-c] pyridine-7-carboxylic acid amide |
AU2006290802B2 (en) * | 2005-09-15 | 2012-06-07 | F. Hoffmann-La Roche Ag | 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
US7932390B2 (en) | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
US7994321B2 (en) * | 2006-08-08 | 2011-08-09 | Hoffmann-La Roche Inc. | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives |
WO2008018881A1 (en) * | 2006-08-10 | 2008-02-14 | Osi Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors |
EP2100895B1 (en) | 2006-12-08 | 2012-03-07 | Takeda Pharmaceutical Company Limited | Tricyclic compound and medical use thereof |
MX2010001636A (en) | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Diazo bicyclic smac mimetics and the uses thereof. |
CA2709664A1 (en) | 2007-12-26 | 2009-07-02 | Eisai R&D Management Co., Ltd. | Method for manufacturing heterocycle substituted pyridine derivatives |
AR070317A1 (en) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | FURO (3,2-C) PIRIDINE AND HAVING (3,2-C) PIRIDINES |
TWI441827B (en) * | 2008-12-05 | 2014-06-21 | Abbvie Bahamas Ltd | Kinase inhibitors with improved cyp safety profile |
WO2012153796A1 (en) | 2011-05-10 | 2012-11-15 | 協和発酵キリン株式会社 | Pyrimido-diazepinone compound |
WO2013012909A1 (en) | 2011-07-20 | 2013-01-24 | Abbott Laboratories | Kinase inhibitor with improved aqueous solubility |
KR101939710B1 (en) | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | Hepatitis b antiviral agents |
AU2013307331A1 (en) | 2012-08-28 | 2015-02-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
EA027194B1 (en) | 2013-02-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
SI3024819T1 (en) | 2013-07-25 | 2018-06-29 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2015059212A1 (en) | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
EP3102225B1 (en) | 2014-02-05 | 2020-03-25 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
WO2015118057A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
EA201792069A1 (en) | 2015-03-19 | 2018-04-30 | Новира Терапьютикс, Инк. | DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017059059A1 (en) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
CN106883270B (en) | 2015-11-26 | 2019-03-26 | 财团法人工业技术研究院 | Organometallic compound and organic light-emitting device including the same |
EP3442524A2 (en) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
KR20200131816A (en) | 2018-03-14 | 2020-11-24 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Capsid assembly modulator dosing regimen |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6369227B1 (en) * | 1998-12-23 | 2002-04-09 | Bristol-Myers Squibb Pharma Company | Thrombin or factor Xa inhibitors |
US20020042409A1 (en) * | 2000-06-06 | 2002-04-11 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH476272A (en) * | 1967-05-12 | 1969-07-31 | Sulzer Ag | Method of making a lining for melting tanks and furnaces |
JPS5813771A (en) * | 1981-07-16 | 1983-01-26 | 平岡織染株式会社 | Connecting of fabric having easily fraying cut end |
JPH0776586A (en) | 1993-07-16 | 1995-03-20 | Yoshitomi Pharmaceut Ind Ltd | Pyridine compound |
US5688355A (en) * | 1994-10-03 | 1997-11-18 | Xerox Corporation | Process for fabricating flexible belts using laser ablation |
US5709765A (en) * | 1994-10-31 | 1998-01-20 | Xerox Corporation | Flexible belt system |
GB9610813D0 (en) | 1996-05-23 | 1996-07-31 | Pharmacia Spa | Combinatorial solid phase synthesis of a library of benzufuran derivatives |
HUP0001507A3 (en) * | 1997-03-19 | 2002-01-28 | Abbott Gmbh & Co Kg | Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them |
ATE241621T1 (en) | 1999-04-02 | 2003-06-15 | Bristol Myers Squibb Pharma Co | ARYLSULFONYLS AS FACTOR XA INHIBITORS |
DK1268481T3 (en) | 1999-09-17 | 2008-05-05 | Abbott Gmbh & Co Kg | Inase inhibitors as therapeutic agents |
MXPA02010550A (en) | 2000-04-28 | 2004-05-17 | Acadia Pharm Inc | Muscarinic agonists. |
US20020079049A1 (en) * | 2000-12-15 | 2002-06-27 | Xerox Corporation | Fabrication method for an electrostatographic member having a virtual flexible seamless substrate (subtantially seamless electrostatographic member fabrication method) |
JPWO2002051849A1 (en) | 2000-12-26 | 2004-04-22 | 第一製薬株式会社 | Cdk4 activity inhibitor |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
US7294457B2 (en) | 2001-08-07 | 2007-11-13 | Boehringer Ingelheim (Canada) Ltd. | Direct binding assay for identifying inhibitors of HCV polymerase |
JP2005508904A (en) * | 2001-09-11 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | Furo- and thienopyrimidine derivatives as angiogenesis inhibitors |
US20050020619A1 (en) | 2003-07-24 | 2005-01-27 | Patrick Betschmann | Thienopyridine kinase inhibitors |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
US20050026944A1 (en) | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
US7123866B2 (en) * | 2004-12-03 | 2006-10-17 | Xerox Corporation | Electrostatic development belt |
US7531283B2 (en) * | 2005-06-20 | 2009-05-12 | Xerox Corporation | Laser ablation of welded seam area |
-
2004
- 2004-04-29 US US10/555,796 patent/US7592352B2/en not_active Expired - Fee Related
- 2004-04-29 WO PCT/US2004/013668 patent/WO2004100947A2/en active Application Filing
- 2004-04-29 JP JP2006532540A patent/JP2006528685A/en active Pending
- 2004-04-29 EP EP04760864A patent/EP1620094A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6369227B1 (en) * | 1998-12-23 | 2002-04-09 | Bristol-Myers Squibb Pharma Company | Thrombin or factor Xa inhibitors |
US20020042409A1 (en) * | 2000-06-06 | 2002-04-11 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
Also Published As
Publication number | Publication date |
---|---|
US20080182868A1 (en) | 2008-07-31 |
EP1620094A4 (en) | 2010-04-28 |
US7592352B2 (en) | 2009-09-22 |
WO2004100947A2 (en) | 2004-11-25 |
JP2006528685A (en) | 2006-12-21 |
EP1620094A2 (en) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004100947A3 (en) | Novel chemical compounds | |
TW200801008A (en) | Protein kinase inhibitors | |
WO2007076423A3 (en) | INHIBITORS OF Akt ACTIVITY | |
MXPA06001134A (en) | INHIBITORS OF Akt ACTIVITY. | |
WO2006004833A3 (en) | Pyrrolotriazine kinase inhibitors | |
WO2003082208A8 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
WO2006138511A3 (en) | Use of hif 1alfa modulators for treatment of cancer | |
WO2005030144A3 (en) | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | |
WO2003084473A3 (en) | Method of treating cancer | |
WO2007064797A3 (en) | Inhibitors of c-met and uses thereof | |
WO2007067781A3 (en) | 9-membered heterobicyclic compounds as inhibitors of protein kinases | |
WO2003073999A3 (en) | Pini-modulating compounds and methods of use thereof | |
WO2004009776A3 (en) | TREATMENT OF TNFα RELATED DISORDERS | |
WO2004047760A3 (en) | Novel chemical compounds | |
WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
WO2006009765A3 (en) | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells | |
WO2004080425A3 (en) | Polypeptide compounds for inhibiting angiogenesis and tumor growth | |
WO2006113837A3 (en) | Inhibitors of akt activity | |
IL178261A0 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy | |
WO2005076854A3 (en) | Pyrimidinone compounds useful as kinase inhibitors | |
WO2003015608A3 (en) | Combination therapy for the treatment of cancer | |
WO2008083326A3 (en) | Targeting of ews-fli1 as anti-tumor therapy | |
ATE428712T1 (en) | 4-AMINO-5-OXO-8-PHENYL-5H-PYRIDO-Ä2,3-DÜ-PYRIMIDINE DERIVATIVES AS INHIBITORS OF TYROSINE KINASES AND RAF KINASES FOR THE TREATMENT OF TUMORS | |
WO2004098377A3 (en) | Methods and compositions for diagnosis and therapy of parkin-associated disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004760864 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10555796 Country of ref document: US Ref document number: 2006532540 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004760864 Country of ref document: EP |